Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Epieriocalyxin A can suppress Caco-2 colon cancer cell growth. It could be a potential drug for colon cancer therapy in the future.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 216.00 | |
5 mg | Inquiry | $ 441.00 | |
10 mg | Inquiry | $ 662.00 |
Description | Epieriocalyxin A can suppress Caco-2 colon cancer cell growth. It could be a potential drug for colon cancer therapy in the future. |
In vitro | Epieriocalyxin A (EpiA), a diterpenoid isolated from I. eriocalyx, suppressed Caco-2 colon cancer cell growth. EpiA induced annexin V flipping in the cell membrane and DNA fragment. We also showed that EpiA induced the generation of ROS in cells, as well as damage of the mitochondrial membrane. Western blot results showed that both JNK and ERK1/2 activation was decreased after EpiA treatment in a dose-dependent manner. EpiA increased the expression of caspase 3 and Bax and decreased Bcl2 expression. |
Source |
Molecular Weight | 344.4 |
Formula | C20H24O5 |
CAS No. | 191545-24-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Epieriocalyxin A 191545-24-1 Apoptosis Cell Cycle/Checkpoint DNA Damage/DNA Repair Immunology/Inflammation MAPK Proteases/Proteasome JNK DNA/RNA Synthesis BCL ERK ROS Caspase diterpenoid Extracellular signal regulated kinases colon cancer ERK1/2 epi-Eriocalyxin A inhibit Inhibitor Bcl-2 inhibitor